nodes	percent_of_prediction	percent_of_DWPC	metapath
Ticagrelor—ABCB1—esophageal cancer	0.786	1	CbGaD
Ticagrelor—Gastrointestinal ulcer haemorrhage—Cisplatin—esophageal cancer	0.00897	0.0645	CcSEcCtD
Ticagrelor—Cardiac tamponade—Methotrexate—esophageal cancer	0.00697	0.0501	CcSEcCtD
Ticagrelor—Renal failure chronic—Cisplatin—esophageal cancer	0.00639	0.0459	CcSEcCtD
Ticagrelor—Gastrointestinal ulcer haemorrhage—Methotrexate—esophageal cancer	0.00492	0.0354	CcSEcCtD
Ticagrelor—Dyspnoea exertional—Capecitabine—esophageal cancer	0.0042	0.0302	CcSEcCtD
Ticagrelor—Nephropathy toxic—Cisplatin—esophageal cancer	0.003	0.0215	CcSEcCtD
Ticagrelor—Serum creatinine increased—Cisplatin—esophageal cancer	0.0028	0.0201	CcSEcCtD
Ticagrelor—Transient ischaemic attack—Capecitabine—esophageal cancer	0.00251	0.0181	CcSEcCtD
Ticagrelor—Serum creatinine increased—Capecitabine—esophageal cancer	0.00206	0.0148	CcSEcCtD
Ticagrelor—Haematoma—Capecitabine—esophageal cancer	0.00202	0.0145	CcSEcCtD
Ticagrelor—Hyperuricaemia—Cisplatin—esophageal cancer	0.00185	0.0133	CcSEcCtD
Ticagrelor—Haematemesis—Capecitabine—esophageal cancer	0.00183	0.0131	CcSEcCtD
Ticagrelor—Metrorrhagia—Capecitabine—esophageal cancer	0.00178	0.0128	CcSEcCtD
Ticagrelor—Blood uric acid increased—Cisplatin—esophageal cancer	0.00175	0.0126	CcSEcCtD
Ticagrelor—Haemoptysis—Capecitabine—esophageal cancer	0.00171	0.0123	CcSEcCtD
Ticagrelor—Vaginal haemorrhage—Capecitabine—esophageal cancer	0.00171	0.0123	CcSEcCtD
Ticagrelor—Body temperature increased—Carboplatin—esophageal cancer	0.00165	0.0119	CcSEcCtD
Ticagrelor—Petechiae—Capecitabine—esophageal cancer	0.00154	0.0111	CcSEcCtD
Ticagrelor—Contusion—Capecitabine—esophageal cancer	0.00145	0.0104	CcSEcCtD
Ticagrelor—Rectal haemorrhage—Capecitabine—esophageal cancer	0.0014	0.0101	CcSEcCtD
Ticagrelor—Cardiac failure congestive—Cisplatin—esophageal cancer	0.00138	0.00989	CcSEcCtD
Ticagrelor—Haematemesis—Methotrexate—esophageal cancer	0.00136	0.00976	CcSEcCtD
Ticagrelor—Renal failure acute—Cisplatin—esophageal cancer	0.00135	0.00972	CcSEcCtD
Ticagrelor—Lung disorder—Methotrexate—esophageal cancer	0.00133	0.00958	CcSEcCtD
Ticagrelor—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.00125	0.00897	CcSEcCtD
Ticagrelor—Melaena—Capecitabine—esophageal cancer	0.00124	0.0089	CcSEcCtD
Ticagrelor—Blood creatinine increased—Cisplatin—esophageal cancer	0.00117	0.0084	CcSEcCtD
Ticagrelor—Petechiae—Methotrexate—esophageal cancer	0.00115	0.00824	CcSEcCtD
Ticagrelor—Ecchymosis—Capecitabine—esophageal cancer	0.00115	0.00824	CcSEcCtD
Ticagrelor—Breast disorder—Cisplatin—esophageal cancer	0.00113	0.00811	CcSEcCtD
Ticagrelor—Bone disorder—Methotrexate—esophageal cancer	0.00105	0.00751	CcSEcCtD
Ticagrelor—Oliguria—Methotrexate—esophageal cancer	0.00102	0.00736	CcSEcCtD
Ticagrelor—Hyperuricaemia—Methotrexate—esophageal cancer	0.00102	0.00731	CcSEcCtD
Ticagrelor—Renal failure acute—Capecitabine—esophageal cancer	0.000997	0.00716	CcSEcCtD
Ticagrelor—Atrial fibrillation—Capecitabine—esophageal cancer	0.000971	0.00698	CcSEcCtD
Ticagrelor—Blood uric acid increased—Methotrexate—esophageal cancer	0.000961	0.00691	CcSEcCtD
Ticagrelor—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—esophageal cancer	0.000956	0.0128	CbGpPWpGaD
Ticagrelor—Cardiac failure—Capecitabine—esophageal cancer	0.000943	0.00678	CcSEcCtD
Ticagrelor—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.000933	0.0125	CbGpPWpGaD
Ticagrelor—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.000933	0.0125	CbGpPWpGaD
Ticagrelor—Melaena—Methotrexate—esophageal cancer	0.000922	0.00662	CcSEcCtD
Ticagrelor—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00092	0.00661	CcSEcCtD
Ticagrelor—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC2—esophageal cancer	0.000892	0.0119	CbGpPWpGaD
Ticagrelor—Bradycardia—Cisplatin—esophageal cancer	0.000879	0.00632	CcSEcCtD
Ticagrelor—ABCB1—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.000873	0.0117	CbGpPWpGaD
Ticagrelor—CYP3A4—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.000865	0.0115	CbGpPWpGaD
Ticagrelor—Blood creatinine increased—Capecitabine—esophageal cancer	0.000862	0.0062	CcSEcCtD
Ticagrelor—Ecchymosis—Methotrexate—esophageal cancer	0.000853	0.00613	CcSEcCtD
Ticagrelor—Urinary tract disorder—Cisplatin—esophageal cancer	0.000853	0.00613	CcSEcCtD
Ticagrelor—Connective tissue disorder—Cisplatin—esophageal cancer	0.000849	0.0061	CcSEcCtD
Ticagrelor—Urethral disorder—Cisplatin—esophageal cancer	0.000847	0.00608	CcSEcCtD
Ticagrelor—Gynaecomastia—Methotrexate—esophageal cancer	0.000845	0.00607	CcSEcCtD
Ticagrelor—Breast disorder—Capecitabine—esophageal cancer	0.000832	0.00598	CcSEcCtD
Ticagrelor—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.000832	0.0111	CbGpPWpGaD
Ticagrelor—P2RY12—Platelet activation, signaling and aggregation—CFL1—esophageal cancer	0.000823	0.011	CbGpPWpGaD
Ticagrelor—Gastritis—Capecitabine—esophageal cancer	0.000815	0.00585	CcSEcCtD
Ticagrelor—Eye disorder—Cisplatin—esophageal cancer	0.000807	0.0058	CcSEcCtD
Ticagrelor—Cardiac disorder—Cisplatin—esophageal cancer	0.000802	0.00576	CcSEcCtD
Ticagrelor—P2RY12—GPCR ligand binding—ADCYAP1—esophageal cancer	0.000798	0.0107	CbGpPWpGaD
Ticagrelor—CYP3A4—Fatty Acid Omega Oxidation—ALDH2—esophageal cancer	0.000796	0.0106	CbGpPWpGaD
Ticagrelor—ABCB1—ABC-family proteins mediated transport—ABCC2—esophageal cancer	0.000795	0.0106	CbGpPWpGaD
Ticagrelor—Immune system disorder—Cisplatin—esophageal cancer	0.00078	0.00561	CcSEcCtD
Ticagrelor—Mediastinal disorder—Cisplatin—esophageal cancer	0.000778	0.00559	CcSEcCtD
Ticagrelor—P2RY12—Platelet activation, signaling and aggregation—GNG7—esophageal cancer	0.000776	0.0104	CbGpPWpGaD
Ticagrelor—Malnutrition—Cisplatin—esophageal cancer	0.000752	0.0054	CcSEcCtD
Ticagrelor—CYP3A4—Fatty Acid Omega Oxidation—CYP2A6—esophageal cancer	0.000749	0.00999	CbGpPWpGaD
Ticagrelor—Renal failure acute—Methotrexate—esophageal cancer	0.000742	0.00533	CcSEcCtD
Ticagrelor—P2RY12—G alpha (i) signalling events—GNG7—esophageal cancer	0.000739	0.00986	CbGpPWpGaD
Ticagrelor—ABCB1—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.000698	0.00932	CbGpPWpGaD
Ticagrelor—Haematuria—Capecitabine—esophageal cancer	0.000676	0.00486	CcSEcCtD
Ticagrelor—P2RY12—Hemostasis—ATP1B2—esophageal cancer	0.000671	0.00896	CbGpPWpGaD
Ticagrelor—Epistaxis—Capecitabine—esophageal cancer	0.000669	0.00481	CcSEcCtD
Ticagrelor—P2RY12—G alpha (i) signalling events—CXCL2—esophageal cancer	0.000651	0.00869	CbGpPWpGaD
Ticagrelor—Bradycardia—Capecitabine—esophageal cancer	0.000648	0.00466	CcSEcCtD
Ticagrelor—Haemoglobin—Capecitabine—esophageal cancer	0.00064	0.0046	CcSEcCtD
Ticagrelor—Haemorrhage—Capecitabine—esophageal cancer	0.000637	0.00457	CcSEcCtD
Ticagrelor—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000636	0.00457	CcSEcCtD
Ticagrelor—P2RY12—Platelet activation, signaling and aggregation—HSPA5—esophageal cancer	0.000633	0.00845	CbGpPWpGaD
Ticagrelor—Urinary tract disorder—Capecitabine—esophageal cancer	0.000629	0.00452	CcSEcCtD
Ticagrelor—Oedema peripheral—Capecitabine—esophageal cancer	0.000627	0.00451	CcSEcCtD
Ticagrelor—CYP3A4—Xenobiotics—CYP2A6—esophageal cancer	0.000626	0.00836	CbGpPWpGaD
Ticagrelor—Connective tissue disorder—Capecitabine—esophageal cancer	0.000626	0.0045	CcSEcCtD
Ticagrelor—Urethral disorder—Capecitabine—esophageal cancer	0.000624	0.00448	CcSEcCtD
Ticagrelor—Breast disorder—Methotrexate—esophageal cancer	0.000619	0.00445	CcSEcCtD
Ticagrelor—P2RY12—Hemostasis—DOCK2—esophageal cancer	0.000607	0.0081	CbGpPWpGaD
Ticagrelor—P2RY12—G alpha (i) signalling events—ANXA1—esophageal cancer	0.000605	0.00808	CbGpPWpGaD
Ticagrelor—CYP3A4—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.000602	0.00804	CbGpPWpGaD
Ticagrelor—Nervous system disorder—Cisplatin—esophageal cancer	0.000602	0.00432	CcSEcCtD
Ticagrelor—Skin disorder—Cisplatin—esophageal cancer	0.000596	0.00428	CcSEcCtD
Ticagrelor—Eye disorder—Capecitabine—esophageal cancer	0.000595	0.00428	CcSEcCtD
Ticagrelor—Cardiac disorder—Capecitabine—esophageal cancer	0.000591	0.00425	CcSEcCtD
Ticagrelor—P2RY12—G alpha (i) signalling events—SST—esophageal cancer	0.000589	0.00786	CbGpPWpGaD
Ticagrelor—Angiopathy—Capecitabine—esophageal cancer	0.000578	0.00415	CcSEcCtD
Ticagrelor—Immune system disorder—Capecitabine—esophageal cancer	0.000575	0.00413	CcSEcCtD
Ticagrelor—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.000575	0.00767	CbGpPWpGaD
Ticagrelor—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.000575	0.00767	CbGpPWpGaD
Ticagrelor—Mediastinal disorder—Capecitabine—esophageal cancer	0.000574	0.00412	CcSEcCtD
Ticagrelor—Hypotension—Cisplatin—esophageal cancer	0.000573	0.00412	CcSEcCtD
Ticagrelor—Mental disorder—Capecitabine—esophageal cancer	0.000558	0.00401	CcSEcCtD
Ticagrelor—Malnutrition—Capecitabine—esophageal cancer	0.000554	0.00398	CcSEcCtD
Ticagrelor—Paraesthesia—Cisplatin—esophageal cancer	0.000551	0.00396	CcSEcCtD
Ticagrelor—CYP3A4—Estrogen metabolism—CYP1B1—esophageal cancer	0.000549	0.00733	CbGpPWpGaD
Ticagrelor—Dyspnoea—Cisplatin—esophageal cancer	0.000547	0.00393	CcSEcCtD
Ticagrelor—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.000538	0.00718	CbGpPWpGaD
Ticagrelor—Back pain—Capecitabine—esophageal cancer	0.000536	0.00385	CcSEcCtD
Ticagrelor—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00053	0.00381	CcSEcCtD
Ticagrelor—P2RY12—Hemostasis—PFN1—esophageal cancer	0.000524	0.00699	CbGpPWpGaD
Ticagrelor—P2RY12—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.000518	0.00691	CbGpPWpGaD
Ticagrelor—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.000512	0.00684	CbGpPWpGaD
Ticagrelor—Feeling abnormal—Cisplatin—esophageal cancer	0.000506	0.00363	CcSEcCtD
Ticagrelor—Haematuria—Methotrexate—esophageal cancer	0.000503	0.00362	CcSEcCtD
Ticagrelor—Epistaxis—Methotrexate—esophageal cancer	0.000498	0.00358	CcSEcCtD
Ticagrelor—Vertigo—Capecitabine—esophageal cancer	0.000498	0.00358	CcSEcCtD
Ticagrelor—Syncope—Capecitabine—esophageal cancer	0.000497	0.00357	CcSEcCtD
Ticagrelor—Loss of consciousness—Capecitabine—esophageal cancer	0.000487	0.0035	CcSEcCtD
Ticagrelor—CYP3A4—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.000485	0.00648	CbGpPWpGaD
Ticagrelor—Body temperature increased—Cisplatin—esophageal cancer	0.000485	0.00349	CcSEcCtD
Ticagrelor—Cough—Capecitabine—esophageal cancer	0.000484	0.00348	CcSEcCtD
Ticagrelor—P2RY12—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.000481	0.00642	CbGpPWpGaD
Ticagrelor—Hypertension—Capecitabine—esophageal cancer	0.000479	0.00344	CcSEcCtD
Ticagrelor—Haemoglobin—Methotrexate—esophageal cancer	0.000476	0.00342	CcSEcCtD
Ticagrelor—Haemorrhage—Methotrexate—esophageal cancer	0.000474	0.00341	CcSEcCtD
Ticagrelor—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—esophageal cancer	0.000473	0.00632	CbGpPWpGaD
Ticagrelor—Chest pain—Capecitabine—esophageal cancer	0.000472	0.00339	CcSEcCtD
Ticagrelor—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000469	0.00337	CcSEcCtD
Ticagrelor—P2RY12—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.000468	0.00625	CbGpPWpGaD
Ticagrelor—Urinary tract disorder—Methotrexate—esophageal cancer	0.000468	0.00336	CcSEcCtD
Ticagrelor—Urethral disorder—Methotrexate—esophageal cancer	0.000465	0.00334	CcSEcCtD
Ticagrelor—P2RY12—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.000456	0.00609	CbGpPWpGaD
Ticagrelor—Confusional state—Capecitabine—esophageal cancer	0.000456	0.00328	CcSEcCtD
Ticagrelor—Hypersensitivity—Cisplatin—esophageal cancer	0.000452	0.00325	CcSEcCtD
Ticagrelor—P2RY12—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.000451	0.00602	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR ligand binding—GNG7—esophageal cancer	0.000447	0.00597	CbGpPWpGaD
Ticagrelor—Shock—Capecitabine—esophageal cancer	0.000445	0.0032	CcSEcCtD
Ticagrelor—Nervous system disorder—Capecitabine—esophageal cancer	0.000444	0.00319	CcSEcCtD
Ticagrelor—Eye disorder—Methotrexate—esophageal cancer	0.000443	0.00318	CcSEcCtD
Ticagrelor—Asthenia—Cisplatin—esophageal cancer	0.00044	0.00316	CcSEcCtD
Ticagrelor—Cardiac disorder—Methotrexate—esophageal cancer	0.00044	0.00316	CcSEcCtD
Ticagrelor—Skin disorder—Capecitabine—esophageal cancer	0.000439	0.00316	CcSEcCtD
Ticagrelor—Angiopathy—Methotrexate—esophageal cancer	0.00043	0.00309	CcSEcCtD
Ticagrelor—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.00043	0.00574	CbGpPWpGaD
Ticagrelor—Immune system disorder—Methotrexate—esophageal cancer	0.000428	0.00308	CcSEcCtD
Ticagrelor—Mediastinal disorder—Methotrexate—esophageal cancer	0.000427	0.00307	CcSEcCtD
Ticagrelor—P2RY12—Hemostasis—CFL1—esophageal cancer	0.000424	0.00567	CbGpPWpGaD
Ticagrelor—Hypotension—Capecitabine—esophageal cancer	0.000423	0.00304	CcSEcCtD
Ticagrelor—Diarrhoea—Cisplatin—esophageal cancer	0.00042	0.00302	CcSEcCtD
Ticagrelor—Mental disorder—Methotrexate—esophageal cancer	0.000415	0.00298	CcSEcCtD
Ticagrelor—Malnutrition—Methotrexate—esophageal cancer	0.000413	0.00296	CcSEcCtD
Ticagrelor—P2RY12—Signaling by GPCR—ADCYAP1—esophageal cancer	0.00041	0.00547	CbGpPWpGaD
Ticagrelor—Paraesthesia—Capecitabine—esophageal cancer	0.000406	0.00292	CcSEcCtD
Ticagrelor—Dyspnoea—Capecitabine—esophageal cancer	0.000403	0.0029	CcSEcCtD
Ticagrelor—P2RY12—Hemostasis—GNG7—esophageal cancer	0.0004	0.00534	CbGpPWpGaD
Ticagrelor—Back pain—Methotrexate—esophageal cancer	0.000399	0.00287	CcSEcCtD
Ticagrelor—Dyspepsia—Capecitabine—esophageal cancer	0.000398	0.00286	CcSEcCtD
Ticagrelor—P2RY12—GPCR ligand binding—CXCL2—esophageal cancer	0.000394	0.00526	CbGpPWpGaD
Ticagrelor—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000391	0.00281	CcSEcCtD
Ticagrelor—Vomiting—Cisplatin—esophageal cancer	0.00039	0.0028	CcSEcCtD
Ticagrelor—Fatigue—Capecitabine—esophageal cancer	0.00039	0.0028	CcSEcCtD
Ticagrelor—Rash—Cisplatin—esophageal cancer	0.000387	0.00278	CcSEcCtD
Ticagrelor—Constipation—Capecitabine—esophageal cancer	0.000387	0.00278	CcSEcCtD
Ticagrelor—Dermatitis—Cisplatin—esophageal cancer	0.000387	0.00278	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—GDI2—esophageal cancer	0.000376	0.00501	CbGpPWpGaD
Ticagrelor—Feeling abnormal—Capecitabine—esophageal cancer	0.000373	0.00268	CcSEcCtD
Ticagrelor—ABCB1—HIF-1-alpha transcription factor network—ENO1—esophageal cancer	0.000371	0.00495	CbGpPWpGaD
Ticagrelor—Vertigo—Methotrexate—esophageal cancer	0.000371	0.00266	CcSEcCtD
Ticagrelor—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00037	0.00266	CcSEcCtD
Ticagrelor—P2RY12—GPCR ligand binding—ANXA1—esophageal cancer	0.000366	0.00489	CbGpPWpGaD
Ticagrelor—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.000365	0.00487	CbGpPWpGaD
Ticagrelor—Nausea—Cisplatin—esophageal cancer	0.000365	0.00262	CcSEcCtD
Ticagrelor—CYP3A4—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.000363	0.00484	CbGpPWpGaD
Ticagrelor—CYP3A4—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00036	0.00481	CbGpPWpGaD
Ticagrelor—Cough—Methotrexate—esophageal cancer	0.00036	0.00259	CcSEcCtD
Ticagrelor—Abdominal pain—Capecitabine—esophageal cancer	0.000358	0.00257	CcSEcCtD
Ticagrelor—Body temperature increased—Capecitabine—esophageal cancer	0.000358	0.00257	CcSEcCtD
Ticagrelor—P2RY12—GPCR ligand binding—SST—esophageal cancer	0.000357	0.00476	CbGpPWpGaD
Ticagrelor—Chest pain—Methotrexate—esophageal cancer	0.000351	0.00252	CcSEcCtD
Ticagrelor—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000349	0.00251	CcSEcCtD
Ticagrelor—P2RY12—GPCR ligand binding—GHRL—esophageal cancer	0.000347	0.00464	CbGpPWpGaD
Ticagrelor—CYP3A4—Tryptophan metabolism—ALDH2—esophageal cancer	0.000342	0.00457	CbGpPWpGaD
Ticagrelor—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—ABL1—esophageal cancer	0.00034	0.00454	CbGpPWpGaD
Ticagrelor—Confusional state—Methotrexate—esophageal cancer	0.00034	0.00244	CcSEcCtD
Ticagrelor—Hypersensitivity—Capecitabine—esophageal cancer	0.000333	0.00239	CcSEcCtD
Ticagrelor—Nervous system disorder—Methotrexate—esophageal cancer	0.00033	0.00237	CcSEcCtD
Ticagrelor—Skin disorder—Methotrexate—esophageal cancer	0.000327	0.00235	CcSEcCtD
Ticagrelor—P2RY12—Hemostasis—HSPA5—esophageal cancer	0.000326	0.00435	CbGpPWpGaD
Ticagrelor—Asthenia—Capecitabine—esophageal cancer	0.000325	0.00233	CcSEcCtD
Ticagrelor—Pruritus—Capecitabine—esophageal cancer	0.00032	0.0023	CcSEcCtD
Ticagrelor—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.000318	0.00425	CbGpPWpGaD
Ticagrelor—Hypotension—Methotrexate—esophageal cancer	0.000315	0.00226	CcSEcCtD
Ticagrelor—Diarrhoea—Capecitabine—esophageal cancer	0.00031	0.00222	CcSEcCtD
Ticagrelor—Paraesthesia—Methotrexate—esophageal cancer	0.000302	0.00217	CcSEcCtD
Ticagrelor—Dyspnoea—Methotrexate—esophageal cancer	0.0003	0.00216	CcSEcCtD
Ticagrelor—Dizziness—Capecitabine—esophageal cancer	0.000299	0.00215	CcSEcCtD
Ticagrelor—Dyspepsia—Methotrexate—esophageal cancer	0.000296	0.00213	CcSEcCtD
Ticagrelor—CYP3A4—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000296	0.00395	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—FKBP1A—esophageal cancer	0.000294	0.00393	CbGpPWpGaD
Ticagrelor—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000291	0.00209	CcSEcCtD
Ticagrelor—P2RY12—GPCR downstream signaling—AKAP13—esophageal cancer	0.000291	0.00388	CbGpPWpGaD
Ticagrelor—Fatigue—Methotrexate—esophageal cancer	0.00029	0.00209	CcSEcCtD
Ticagrelor—Vomiting—Capecitabine—esophageal cancer	0.000288	0.00207	CcSEcCtD
Ticagrelor—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000285	0.00381	CbGpPWpGaD
Ticagrelor—Rash—Capecitabine—esophageal cancer	0.000285	0.00205	CcSEcCtD
Ticagrelor—Dermatitis—Capecitabine—esophageal cancer	0.000285	0.00205	CcSEcCtD
Ticagrelor—Headache—Capecitabine—esophageal cancer	0.000283	0.00204	CcSEcCtD
Ticagrelor—Feeling abnormal—Methotrexate—esophageal cancer	0.000278	0.00199	CcSEcCtD
Ticagrelor—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000275	0.00198	CcSEcCtD
Ticagrelor—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000272	0.00363	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—KMT2D—esophageal cancer	0.000271	0.00362	CbGpPWpGaD
Ticagrelor—ABCB1—HIF-1-alpha transcription factor network—HMOX1—esophageal cancer	0.00027	0.00361	CbGpPWpGaD
Ticagrelor—Nausea—Capecitabine—esophageal cancer	0.000269	0.00193	CcSEcCtD
Ticagrelor—Abdominal pain—Methotrexate—esophageal cancer	0.000266	0.00191	CcSEcCtD
Ticagrelor—Body temperature increased—Methotrexate—esophageal cancer	0.000266	0.00191	CcSEcCtD
Ticagrelor—P2RY12—GPCR downstream signaling—PDE4D—esophageal cancer	0.000266	0.00355	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—AKAP13—esophageal cancer	0.000264	0.00352	CbGpPWpGaD
Ticagrelor—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.00026	0.00347	CbGpPWpGaD
Ticagrelor—ABCB1—HIF-1-alpha transcription factor network—SMAD4—esophageal cancer	0.00026	0.00346	CbGpPWpGaD
Ticagrelor—CYP3A4—Tryptophan metabolism—CYP1B1—esophageal cancer	0.000259	0.00346	CbGpPWpGaD
Ticagrelor—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000257	0.00343	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—GNG7—esophageal cancer	0.000253	0.00337	CbGpPWpGaD
Ticagrelor—Hypersensitivity—Methotrexate—esophageal cancer	0.000248	0.00178	CcSEcCtD
Ticagrelor—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.000244	0.00325	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—ADCYAP1—esophageal cancer	0.000242	0.00323	CbGpPWpGaD
Ticagrelor—Asthenia—Methotrexate—esophageal cancer	0.000242	0.00174	CcSEcCtD
Ticagrelor—P2RY12—Hemostasis—ABL1—esophageal cancer	0.000242	0.00322	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—PDE4D—esophageal cancer	0.000241	0.00322	CbGpPWpGaD
Ticagrelor—Pruritus—Methotrexate—esophageal cancer	0.000238	0.00171	CcSEcCtD
Ticagrelor—Diarrhoea—Methotrexate—esophageal cancer	0.00023	0.00166	CcSEcCtD
Ticagrelor—P2RY12—Signaling by GPCR—GNG7—esophageal cancer	0.00023	0.00306	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	0.000229	0.00305	CbGpPWpGaD
Ticagrelor—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000224	0.00299	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—CXCL2—esophageal cancer	0.000223	0.00297	CbGpPWpGaD
Ticagrelor—Dizziness—Methotrexate—esophageal cancer	0.000223	0.0016	CcSEcCtD
Ticagrelor—P2RY12—Signaling Pathways—WWOX—esophageal cancer	0.000221	0.00295	CbGpPWpGaD
Ticagrelor—Vomiting—Methotrexate—esophageal cancer	0.000214	0.00154	CcSEcCtD
Ticagrelor—ABCB1—HIF-1-alpha transcription factor network—HIF1A—esophageal cancer	0.000212	0.00284	CbGpPWpGaD
Ticagrelor—Rash—Methotrexate—esophageal cancer	0.000212	0.00153	CcSEcCtD
Ticagrelor—Dermatitis—Methotrexate—esophageal cancer	0.000212	0.00152	CcSEcCtD
Ticagrelor—Headache—Methotrexate—esophageal cancer	0.000211	0.00152	CcSEcCtD
Ticagrelor—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000211	0.00281	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—FKBP1A—esophageal cancer	0.000211	0.00281	CbGpPWpGaD
Ticagrelor—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.00021	0.0028	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—ANXA1—esophageal cancer	0.000207	0.00276	CbGpPWpGaD
Ticagrelor—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000207	0.00276	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—WIF1—esophageal cancer	0.000206	0.00275	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—CXCL2—esophageal cancer	0.000202	0.0027	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—SST—esophageal cancer	0.000201	0.00269	CbGpPWpGaD
Ticagrelor—Nausea—Methotrexate—esophageal cancer	0.0002	0.00144	CcSEcCtD
Ticagrelor—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.0002	0.00267	CbGpPWpGaD
Ticagrelor—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000197	0.00263	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—GHRL—esophageal cancer	0.000196	0.00262	CbGpPWpGaD
Ticagrelor—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000194	0.0026	CbGpPWpGaD
Ticagrelor—ABCB1—HIF-1-alpha transcription factor network—NOS2—esophageal cancer	0.000193	0.00258	CbGpPWpGaD
Ticagrelor—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000193	0.00257	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—CSNK1A1—esophageal cancer	0.00019	0.00253	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—ANXA1—esophageal cancer	0.000188	0.00251	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—SST—esophageal cancer	0.000183	0.00244	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—GHRL—esophageal cancer	0.000178	0.00238	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PFN1—esophageal cancer	0.000178	0.00237	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—NOS2—esophageal cancer	0.000174	0.00232	CbGpPWpGaD
Ticagrelor—ABCB1—HIF-1-alpha transcription factor network—CREBBP—esophageal cancer	0.000174	0.00232	CbGpPWpGaD
Ticagrelor—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.00017	0.00227	CbGpPWpGaD
Ticagrelor—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000169	0.00226	CbGpPWpGaD
Ticagrelor—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.00016	0.00213	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—ELMO1—esophageal cancer	0.00016	0.00213	CbGpPWpGaD
Ticagrelor—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.000157	0.0021	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—CREBBP—esophageal cancer	0.000156	0.00209	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—AKAP13—esophageal cancer	0.000156	0.00208	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	0.000155	0.00207	CbGpPWpGaD
Ticagrelor—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000155	0.00207	CbGpPWpGaD
Ticagrelor—P2RY12—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	0.000153	0.00204	CbGpPWpGaD
Ticagrelor—ABCB1—Allograft Rejection—CASP8—esophageal cancer	0.000151	0.00201	CbGpPWpGaD
Ticagrelor—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.000146	0.00195	CbGpPWpGaD
Ticagrelor—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000144	0.00192	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000144	0.00192	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PDE4D—esophageal cancer	0.000143	0.0019	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	0.000142	0.0019	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—NOS3—esophageal cancer	0.00014	0.00187	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—GNG7—esophageal cancer	0.000136	0.00181	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.000135	0.0018	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000134	0.00179	CbGpPWpGaD
Ticagrelor—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—esophageal cancer	0.000131	0.00174	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—XIAP—esophageal cancer	0.000127	0.0017	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000126	0.00169	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—CTNNA1—esophageal cancer	0.00012	0.0016	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.00012	0.0016	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—CXCL2—esophageal cancer	0.00012	0.0016	CbGpPWpGaD
Ticagrelor—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000119	0.00159	CbGpPWpGaD
Ticagrelor—ABCB1—HIF-1-alpha transcription factor network—EP300—esophageal cancer	0.000118	0.00158	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	0.000115	0.00153	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000114	0.00152	CbGpPWpGaD
Ticagrelor—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000113	0.00151	CbGpPWpGaD
Ticagrelor—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.000112	0.00149	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PSME1—esophageal cancer	0.000112	0.00149	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PSME2—esophageal cancer	0.000112	0.00149	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—ANXA1—esophageal cancer	0.000111	0.00148	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	0.000111	0.00148	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.00011	0.00146	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.00011	0.00146	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—SST—esophageal cancer	0.000108	0.00144	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—EP300—esophageal cancer	0.000107	0.00142	CbGpPWpGaD
Ticagrelor—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000106	0.00142	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—NOTCH3—esophageal cancer	0.000105	0.00141	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—GHRL—esophageal cancer	0.000105	0.00141	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	0.000105	0.0014	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—FBXW7—esophageal cancer	0.000104	0.00138	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—NOTCH2—esophageal cancer	9.45e-05	0.00126	CbGpPWpGaD
Ticagrelor—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	9.03e-05	0.0012	CbGpPWpGaD
Ticagrelor—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	8.9e-05	0.00119	CbGpPWpGaD
Ticagrelor—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	8.49e-05	0.00113	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—TGFBR2—esophageal cancer	8.38e-05	0.00112	CbGpPWpGaD
Ticagrelor—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	8.37e-05	0.00112	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	8.3e-05	0.00111	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—SMAD4—esophageal cancer	7.93e-05	0.00106	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—PIK3CA—esophageal cancer	7.88e-05	0.00105	CbGpPWpGaD
Ticagrelor—P2RY12—Hemostasis—TP53—esophageal cancer	7.62e-05	0.00102	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—GNG7—esophageal cancer	7.53e-05	0.00101	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	7.45e-05	0.000994	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	7.42e-05	0.00099	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—BLVRB—esophageal cancer	7.4e-05	0.000988	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—SLC52A3—esophageal cancer	7.4e-05	0.000988	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—HIF1A—esophageal cancer	6.49e-05	0.000866	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	6.39e-05	0.000853	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—CA1—esophageal cancer	6.29e-05	0.00084	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—SLC10A2—esophageal cancer	6.29e-05	0.00084	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	6.21e-05	0.000829	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—KDR—esophageal cancer	6.21e-05	0.000829	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	6.07e-05	0.00081	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—NOTCH1—esophageal cancer	5.85e-05	0.00078	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—CA2—esophageal cancer	5.76e-05	0.000768	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	5.49e-05	0.000732	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—ADH7—esophageal cancer	5.35e-05	0.000714	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PLCE1—esophageal cancer	5.35e-05	0.000714	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	5.31e-05	0.000708	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—CREBBP—esophageal cancer	5.3e-05	0.000708	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—EGFR—esophageal cancer	5.21e-05	0.000695	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	5.05e-05	0.000674	CbGpPWpGaD
Ticagrelor—P2RY12—GPCR downstream signaling—PIK3CA—esophageal cancer	4.98e-05	0.000665	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—NOS3—esophageal cancer	4.75e-05	0.000634	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—ADH1B—esophageal cancer	4.69e-05	0.000626	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	4.59e-05	0.000613	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—BLVRB—esophageal cancer	4.56e-05	0.000609	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—SLC52A3—esophageal cancer	4.56e-05	0.000609	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling by GPCR—PIK3CA—esophageal cancer	4.52e-05	0.000604	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—TYMP—esophageal cancer	4.48e-05	0.000599	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—ERBB2—esophageal cancer	4.44e-05	0.000593	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	4.4e-05	0.000587	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—CYP26A1—esophageal cancer	4.36e-05	0.000582	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	4.3e-05	0.000575	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—ALOX15—esophageal cancer	4.25e-05	0.000567	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—GSTO1—esophageal cancer	4.06e-05	0.000541	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—TPI1—esophageal cancer	4.06e-05	0.000541	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—CCND1—esophageal cancer	3.92e-05	0.000524	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—ALDOB—esophageal cancer	3.89e-05	0.000519	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—CA1—esophageal cancer	3.88e-05	0.000518	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—SLC10A2—esophageal cancer	3.88e-05	0.000518	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—CDKN1A—esophageal cancer	3.79e-05	0.000506	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—GAPDH—esophageal cancer	3.74e-05	0.0005	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	3.74e-05	0.000499	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—CRABP1—esophageal cancer	3.71e-05	0.000495	CbGpPWpGaD
Ticagrelor—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	3.61e-05	0.000482	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—EP300—esophageal cancer	3.61e-05	0.000482	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—CA2—esophageal cancer	3.55e-05	0.000473	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—GNG7—esophageal cancer	3.53e-05	0.000471	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—ALDH2—esophageal cancer	3.31e-05	0.000441	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—ADH7—esophageal cancer	3.3e-05	0.00044	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PLCE1—esophageal cancer	3.3e-05	0.00044	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—MYC—esophageal cancer	3.15e-05	0.00042	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—GSTT1—esophageal cancer	3.14e-05	0.00042	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—CYP2A6—esophageal cancer	3.11e-05	0.000415	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—EGFR—esophageal cancer	3.08e-05	0.000411	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—ENO1—esophageal cancer	2.95e-05	0.000393	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PTGS1—esophageal cancer	2.95e-05	0.000393	CbGpPWpGaD
Ticagrelor—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.94e-05	0.000393	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PSME1—esophageal cancer	2.9e-05	0.000388	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PSME2—esophageal cancer	2.9e-05	0.000388	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—ADH1B—esophageal cancer	2.89e-05	0.000386	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—TYMP—esophageal cancer	2.76e-05	0.000369	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—CYP26A1—esophageal cancer	2.69e-05	0.000359	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—PIK3CA—esophageal cancer	2.67e-05	0.000357	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—ALOX15—esophageal cancer	2.62e-05	0.00035	CbGpPWpGaD
Ticagrelor—P2RY12—Signaling Pathways—TP53—esophageal cancer	2.58e-05	0.000345	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—CYP1B1—esophageal cancer	2.51e-05	0.000334	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—TPI1—esophageal cancer	2.5e-05	0.000333	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—GSTO1—esophageal cancer	2.5e-05	0.000333	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—ALDOB—esophageal cancer	2.4e-05	0.00032	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—CYP19A1—esophageal cancer	2.36e-05	0.000314	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—GAPDH—esophageal cancer	2.31e-05	0.000308	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—CRABP1—esophageal cancer	2.29e-05	0.000305	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—GNG7—esophageal cancer	2.17e-05	0.00029	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—HMOX1—esophageal cancer	2.15e-05	0.000287	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—ALDH2—esophageal cancer	2.04e-05	0.000272	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.94e-05	0.000259	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.92e-05	0.000256	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—ENO1—esophageal cancer	1.82e-05	0.000242	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.82e-05	0.000242	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PSME2—esophageal cancer	1.79e-05	0.000239	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PSME1—esophageal cancer	1.79e-05	0.000239	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.54e-05	0.000206	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.45e-05	0.000194	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—CREBBP—esophageal cancer	1.38e-05	0.000184	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—HMOX1—esophageal cancer	1.32e-05	0.000177	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—ABCB1—esophageal cancer	1.27e-05	0.00017	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—NOS3—esophageal cancer	1.23e-05	0.000165	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PTGS2—esophageal cancer	1.13e-05	0.000151	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—EP300—esophageal cancer	9.39e-06	0.000125	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—CREBBP—esophageal cancer	8.5e-06	0.000113	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—NOS3—esophageal cancer	7.61e-06	0.000102	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PTGS2—esophageal cancer	6.96e-06	9.29e-05	CbGpPWpGaD
Ticagrelor—ABCB1—Metabolism—PIK3CA—esophageal cancer	6.95e-06	9.27e-05	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—EP300—esophageal cancer	5.79e-06	7.72e-05	CbGpPWpGaD
Ticagrelor—CYP3A4—Metabolism—PIK3CA—esophageal cancer	4.28e-06	5.71e-05	CbGpPWpGaD
